Antibiotic Resistance: Finding the right sequence of drugs
Rapidly switching between similar antibiotics may help to slow down the evolution of resistance.
- Department of Biophysics, University of Michigan, United States
- Department of Physics, University of Michigan, United States
In order to survive, many living organisms need to be able to adapt to their ever-changing environment. These past experiences shape the behavior of creatures big and small – from mutations in single genes to neurological changes that underlie memory formation in primates.
There is substantial evidence that environmental history affects how bacteria respond to antibiotics (Barbosa et al., 2019; Card et al., 2019; Nichol et al., 2019; Santos-Lopez et al., 2019; Yen and Papin, 2017). This has led researchers to suggest that switching between drugs over time could help slow down antibiotic resistance, as this will force the bacteria into a scenario where their existing solutions (resistance to the current drug) cannot protect them from tomorrow’s problem (a new drug). However, this method has led to mixed results (Abel zur Wiesch et al., 2014; Imamovic et al., 2018), and optimizing this approach is challenging, in part because it is unclear which features of the antibiotic sequence are the most important and guarantee the best results.
Now, in eLife, Hinrich Schulenburg (University of Kiel and Max Planck Institute for Evolutionary Biology) and colleagues – including Aditi Batra and Roderich Roemhild as joint first authors – report the results of experiments on the multi-drug resistant bacteria Pseudomonas aeruginosa (Batra et al., 2021). The team (who are based in Austria and Germany) exposed the bacteria to various sequences of three antibiotics that belong to commonly used classes of drugs: one class targets the ribosome, one targets DNA gyrase, and one targets the cell wall. In some cases, three drugs from different classes were used (that is, a heterogeneous sequence), and in some cases all three drugs belonged to the same class (a homogenous sequence). Batra et al. also varied the temporal properties of each sequence by switching between the drugs rapidly, slowly, or in a random order. The growth rate, phenotypic resistance levels and population genetics of the evolved populations were then analyzed to determine which sequences of drugs were the most effective at eliminating the bacteria (Figure 1A).
Figure 1
Experimental and biological features of effective drug sequences.
(A) Batra et al. applied different sequences of antibiotics to 756 populations of P. aeruginosa (top panel). The bacteria were treated with either a single drug (monotherapy; row 1), or three antibiotics which were switched rapidly (row 2), slowly (row 3) or in a random order (row 4): the three drugs were either from the same class (homogeneous) or from different classes (heterogeneous). This experiment revealed that fast (blue line) and random (green line) switching between three homogeneous beta-lactam drugs reduced bacteria growth and resulted in higher levels of extinction (bottom graph). (B) The effects of the different sequences are also impacted by biological features. (Top panel) When sensitive bacteria (shown in purple) are treated with the first drug, some cells will evolve genetic changes that make them resistant to the antibiotic treatment (shown in green). These evolutionary changes can lead to collateral effects that make the bacteria less (top arrow), equally (middle arrow) or more (bottom arrow) resistant to the second drug. (Bottom panel) Treatment with the first drug may also lead to negative hysteresis, when short-term physiological changes enhance the bacteria’s response to the second drug (right), leading to more cell death in the population compared to bacteria not pre-treated with the first drug (left).
Image credit: Anh Huynh.
In addition to these experimental parameters, the impact of different antibiotic sequences could also depend on how the population biologically responds to consecutive drug exposures (Figure 1B). For example, the genetic changes bacteria evolve in response to one antibiotic can lead to collateral effects that increase the population’s resistance or sensitivity to another drug. Because collateral resistance occurs more frequently between drugs of the same class, heterogeneous sequences of antibiotics are thought to be more effective at eliminating bacteria (Imamovic and Sommer, 2013; Lázár et al., 2013; Maltas and Wood, 2019; Pál et al., 2015; Lázár et al., 2014). Treatment with unrelated drugs has also been shown to favor negative hysteresis, which is when short-term physiological changes induced by one antibiotic enhance susceptibility towards another. Indeed, a recent study found that rapid switching between antibiotics from different classes promoted extinction of bacterial populations, even when the drugs were used at sub-inhibitory levels (Roemhild et al., 2018).
However, Batra et al. found that homogenous sequences of beta-lactams (a class of antibiotics that target the cell wall) were surprisingly more effective at clearing bacteria. The experiments also revealed that extinction tended to occur early in the treatment and was less effective when drugs were switched more slowly. A particular heterogeneous set of drugs also tended to not eliminate bacteria, indicating that heterogeneity, alone, does not guarantee success.
So, what are the important characteristics of a ‘good’ antibiotic sequence? To answer this question, Batra et al. used a common class of statistical models to probe for signatures of successful sequences. They found that extinction was strongly favored by two biological properties — low rates of spontaneous resistance and low levels of collateral resistance — and was also enhanced when switching between drugs was fast or random. This suggests that although thefindings of Batra et al. contradict the proposed benefits of using unrelated drugs, they still validate a portion of the underlying logic: using antibiotics with strong collateral effects and hysteresis enhances the impact of sequence therapy. It just turns out, however, that drugs with these characteristics are not always from different classes.
This study offers insight into how past antibiotic exposure shapes the response of bacterial populations to new challenges. In doing so, it provides a roadmap for future studies investigating how even the simplest organisms harbor signatures of past challenges and potential evolutionary solutions.
References
-
Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance developmentScience Translational Medicine 5:204ra132.https://doi.org/10.1126/scitranslmed.3006609
-
Bacterial evolution of antibiotic hypersensitivityMolecular Systems Biology 9:700.https://doi.org/10.1038/msb.2013.57
-
Collateral sensitivity of antibiotic-resistant microbesTrends in Microbiology 23:401–407.https://doi.org/10.1016/j.tim.2015.02.009
Article and author information
Author details
Publication history
Copyright
© 2021, Huynh and Wood
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,213
- views
-
- 88
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Antibiotic Resistance: Finding the right sequence of drugs
eLife 10:e72562.
https://doi.org/10.7554/eLife.72562
Further reading
-
- Evolutionary Biology
Lineages of rod-shaped bacteria such as Escherichia coli exhibit a temporal decline in elongation rate in a manner comparable to cellular or biological aging. The effect results from the production of asymmetrical daughters, one with a lower elongation rate, by the division of a mother cell. The slower daughter compared to the faster daughter, denoted respectively as the old and new daughters, has more aggregates of damaged proteins and fewer expressed gene products. We have examined further the degree of asymmetry by measuring the density of ribosomes between old and new daughters and between their poles. We found that ribosomes were denser in the new daughter and also in the new pole of the daughters. These ribosome patterns match the ones we previously found for expressed gene products. This outcome suggests that the asymmetry is not likely to result from properties unique to the gene expressed in our previous study, but rather from a more fundamental upstream process affecting the distribution of ribosomal abundance. Because damage aggregates and ribosomes are both more abundant at the poles of E. coli cells, we suggest that competition for space between the two could explain the reduced ribosomal density in old daughters. Using published values for aggregate sizes and the relationship between ribosomal number and elongation rates, we show that the aggregate volumes could in principle displace quantitatively the amount of ribosomes needed to reduce the elongation rate of the old daughters.
-
- Evolutionary Biology
- Genetics and Genomics
Evolutionary arms races can arise at the contact surfaces between host and viral proteins, producing dynamic spaces in which genetic variants are continually pursued. However, the sampling of genetic variation must be balanced with the need to maintain protein function. A striking case is given by protein kinase R (PKR), a member of the mammalian innate immune system. PKR detects viral replication within the host cell and halts protein synthesis to prevent viral replication by phosphorylating eIF2α, a component of the translation initiation machinery. PKR is targeted by many viral antagonists, including poxvirus pseudosubstrate antagonists that mimic the natural substrate, eIF2α, and inhibit PKR activity. Remarkably, PKR has several rapidly evolving residues at this interface, suggesting it is engaging in an evolutionary arms race, despite the surface’s critical role in phosphorylating eIF2α. To systematically explore the evolutionary opportunities available at this dynamic interface, we generated and characterized a library of 426 SNP-accessible nonsynonymous variants of human PKR for their ability to escape inhibition by the model pseudosubstrate inhibitor K3, encoded by the vaccinia virus gene K3L. We identified key sites in the PKR kinase domain that harbor K3-resistant variants, as well as critical sites where variation leads to loss of function. We find K3-resistant variants are readily available throughout the interface and are enriched at sites under positive selection. Moreover, variants beneficial against K3 were also beneficial against an enhanced variant of K3, indicating resilience to viral adaptation. Overall, we find that the eIF2α-binding surface of PKR is highly malleable, potentiating its evolutionary ability to combat viral inhibition.
